Hemolytic anemia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Categories)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Hemolytic anemia}}
{{Hemolytic anemia}}
{{CMG}}
{{CMG}}


Line 18: Line 17:


The drug itself can be targeted by the [[immune system]], e.g. by [[IgE]] in a [[Type I hypersensitivity reaction]] to [[penicillin]], rarely leading to [[anaphylaxis]].
The drug itself can be targeted by the [[immune system]], e.g. by [[IgE]] in a [[Type I hypersensitivity reaction]] to [[penicillin]], rarely leading to [[anaphylaxis]].
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Hematology]]
{{WS}}
{{WH}}

Revision as of 16:22, 17 June 2016

Hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT Scan

MRI Scan

Echocardiography or Ultrasound

Imaging Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic anemia differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic anemia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic anemia differential diagnosis

CDC on Hemolytic anemia differential diagnosis

Hemolytic anemia differential diagnosis in the news

Blogs on Hemolytic anemia differential diagnosis

Directions to Hospitals Treating Hemolytic anemia

Risk calculators and risk factors for Hemolytic anemia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Differentiating Hemolytic anemia from other Diseases

Differentiating Drug-Induced Autoimmune Hemolytic Anemia from other Diseases

Penicillin in high doses can induce immune mediated hemolysis[1] via the hapten mechanism in which antibodies are targeted against the combination of penicillin in association with red blood cells. Complement is activated by the attached antibody leading to the removal of red blood cells by the spleen.

The drug itself can be targeted by the immune system, e.g. by IgE in a Type I hypersensitivity reaction to penicillin, rarely leading to anaphylaxis.

References

  1. Stroncek D, Procter JL, Johnson J (2000). <67::AID-AJH12>3.0.CO;2-Z "Drug-induced hemolysis: cefotetan-dependent hemolytic anemia mimicking an acute intravascular immune transfusion reaction". Am. J. Hematol. 64 (1): 67–70. PMID 10815791. Unknown parameter |month= ignored (help)

Template:WS Template:WH